EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension

Pantelis Sarafidis iD, Roland Schmieder, Michel Burnier iD, Alexandre Persu, Andrzej Januszewicz, Jean-Michel Halimi, Mustafa Arici, Alberto Ortiz iD, Christoph Wanner iD, Giuseppe Mancia iD, Reinhold Kreutz

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae041 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Pantelis Sarafidis und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Hypertension, Nephrology, Societies, Medical. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In June 2023, the European Society of Hypertension (ESH) presented and published the new 2023 ESH Guidelines for the Management of Arterial Hypertension, a document that was endorsed by the European Renal Association (ERA). Following the evolution of evidence in recent years, several novel recommendations relevant to the management of hypertension in patients with chronic kidney disease (CKD) appeared in these Guidelines. These include recommendations for target office blood pressure (BP) <130/80 mmHg in most and against target office BP <120/70 mmHg in all patients with CKD; recommendations for use of spironolactone or chlorthalidone for patients with resistant hypertension with estimated glomerular filtration rate (eGFR) higher or lower than 30 mL/min/1.73 m2, respectively; use of a sodium-glucose cotransporter 2 inhibitor for patients with CKD and estimated eGFR ≥20 mL/min/1.73 m2; use of finerenone for patients with CKD, type 2 diabetes mellitus, albuminuria, eGFR ≥25 mL/min/1.73 m2 and serum potassium <5.0 mmol/L; and revascularization in patients with atherosclerotic renovascular disease and secondary hypertension or high-risk phenotypes if stenosis ≥70% is present. The present report is a synopsis of sections of the ESH Guidelines that are relevant to the daily clinical practice of nephrologists, prepared by experts from ESH and ERA. The sections summarized are those referring to the role of CKD in hypertension staging and cardiovascular risk stratification, the evaluation of hypertension-mediated kidney damage and the overall management of hypertension in patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionNephrologySocieties, MedicalHumansEuropeAntihypertensive AgentsRenal Insufficiency, Chronic

Stichwörter der Autor:innen

albuminuriablood pressurechronic kidney diseasehypertensionhypertensive kidney disease

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • 1st Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
  • Department of Nephrology and Hypertension, University Hospital Erlangen, Germany.
  • Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
  • Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
  • Service de Néphrologie-Hypertension, Dialyses, Transplantation rénale, CHRU Tours, Tours, France and INSERM SPHERE U1246, Université Tours, Université de Nantes, Tours, France.

ORCID-Profile: Pantelis Sarafidis, Michel Burnier, Alberto Ortiz, Christoph Wanner, Giuseppe Mancia

Zitieren

APA

Sarafidis, P., Schmieder, R., Burnier, M., Persu, A., Januszewicz, A., Halimi, J. M., Arici, M., Ortiz, A., Wanner, C., Mancia, G., & Kreutz, R. (2024). A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae041

Vancouver

Sarafidis P, Schmieder R, Burnier M, Persu A, Januszewicz A, Halimi JM, et al. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae041

BibTeX
@article{Sarafidis2024,
  author = {Sarafidis, Pantelis and Schmieder, Roland and Burnier, Michel and Persu, Alexandre and Januszewicz, Andrzej and Halimi, Jean-Michel and Arici, Mustafa and Ortiz, Alberto and Wanner, Christoph and Mancia, Giuseppe and Kreutz, Reinhold},
  title = {A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae041}
}
Kostenlos starten →